Drug Trial Radar · NCT00468728
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
535
Actual
Start
Oct 4, 2006
Primary completion
Dec 11, 2009
Study completion Dec 11, 2009
Sponsor
- Lead sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- May 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
Conditions
- Clostridium Infections
- Diarrhea
Interventions
PAR-101/OPT-80Drug
capsules
VancomycinDrug
Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure Rate at End of TherapyTime frame: Study day 10 (+/- 2 days)
Locations
116 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Gadsden, Alabama
Site not named
Phoenix, Arizona
Site not named
Hot Springs, Arkansas
Site not named
La Mesa, California
Site not named
Modesto, California
Site not named
Palm Springs, California
Site not named
Rancho Mirage, California
Site not named
San Jose, California
Site not named
Santa Ana, California
Site not named
Vallejo, California
Site not named
Washington D.C., District of Columbia
Site not named
Miami, Florida
Site not named
Port Orange, Florida
Site not named
Sarasota, Florida
Site not named
Marietta, Georgia
Site not named
Savannah, Georgia
Site not named
Idaho Falls, Idaho
Site not named
Chicago, Illinois
Site not named
Maywood, Illinois
Site not named
Indianapolis, Indiana
Site not named
Bowling Green, Kentucky
Site not named
Jena, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
West Roxbury, Massachusetts
Site not named
Detroit, Michigan
Site not named
Keego Harbor, Michigan
Site not named
Royal Oak, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Tupelo, Mississippi
Site not named
Columbia, Missouri
Site not named
Butte, Montana
Site not named
Cedar Knolls, New Jersey
Site not named
Neptune City, New Jersey
Site not named
The Bronx, New York
Site not named
Charlotte, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Fargo, North Dakota
Site not named
Akron, Ohio
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.